molecules-logo

Journal Browser

Journal Browser

Plant Product- and/or Synthetic Compound-Based Drug Development for Livestock Disease Treatment

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 31 May 2025 | Viewed by 417

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskisehir, Turkey
Interests: medicinal chemistry; computational chemistry; QSAR; molecular modelling; molecular simulations; virtual screening; in silico ADME analysis; drug design and development
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Department of Molecular Biology and Genetics, Burdur Mehmet Akif Ersoy University, Burdur 15030, Türkiye
2. Department of Bioengineering Sciences, Izmir Katip Celebi University, Izmir 35620, Türkiye
3. Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto 862-0976, Japan
4. Department of Drug Discovery, Science Farm Ltd., Kumamoto 862-0976, Japan
Interests: structure-based drug discovery; molecular simulations; drug repositioning; structural biology; molecular modelling; QSAR; virtual screening
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca, 400372 Cluj-Napoca, Romania
Interests: livestock health and management; drug design and development; nanomedicine; flow cytometry; molecular biology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

There are both similarities and differences between animal and human drug development processes. Although the pharmaceutical industry is generally devoted to human healthcare, the value of veterinary pharmaceutical is undisputed.

Some drugs are used for stopping the onset and progression of disease, whereas some of them are administered for growth promotion, particularly in food animals. These drugs can cause adverse effects to both medicated animals and the people who consume them.

Livestock production is a very important means of livelihood for people in the world. There are several pathogenic and metabolic disorders that affect these animals severely, threatening animal health and strength of the economy. In general, antimicrobials are commonly used for prophylactic and curative purposes. The excessive use of antimicrobials in livestock can transmit to people, resulting in the emergence of resistant bacteria. As such, it is an unmet need to discover new therapeutics in order to control disorders in livestock.

Natural products are great sources for the development of new therapeutic candidates as well as synthetic compounds.

Therefore, this Special Issue aims to discover new therapeutics for the treatment of livestock diseases. It is our great pleasure to invite you to submit original research articles and reviews, which will be published in this Special Issue titled “Plant Product- and/or Synthetic Compound-Based Drug Development for Livestock Disease Treatment”.

Dr. Belgin Sever
Dr. Halil İbrahim Ciftci
Prof. Dr. Mihai Cosmin Cenariu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • viral diseases
  • bacterial diseases
  • fungal diseases
  • protozoan diseases
  • metabolic disorders
  • reproductive disorders

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 5922 KiB  
Article
Gypenosides Attenuates CORT-Induced Ferroptosis via Inhibiting TNF-α/NF-κB Signaling Pathway in PC12 Cells
by Lingling Dai, Jinghui Peng, Manyu Zhang, Yulin Hu, Zhicheng Gao, Jibin Wang, Haiyang Zhang and Shoujun Li
Molecules 2025, 30(10), 2103; https://doi.org/10.3390/molecules30102103 - 9 May 2025
Viewed by 163
Abstract
Chronic stress can lead to nervous system dysfunction and depression-like behaviors in animals. Gypenosides can improve chronic stress-induced neuronal damage, but the protective mechanism remains poorly understood. This study aims to investigate the effect and mechanism of gypenosides on chronic stress-induced neuronal ferroptosis. [...] Read more.
Chronic stress can lead to nervous system dysfunction and depression-like behaviors in animals. Gypenosides can improve chronic stress-induced neuronal damage, but the protective mechanism remains poorly understood. This study aims to investigate the effect and mechanism of gypenosides on chronic stress-induced neuronal ferroptosis. Therefore, we established a chronic stress-induced neuronal damage model in vitro using corticosterone to induce PC12 cell injury. We demonstrated that ferroptosis inhibitors DFO and Ferrostatin-1 alleviated corticosterone-induced cell death in PC12 cells by reducing iron accumulation, lipid peroxidation, and increasing cell viability. Meanwhile, gypenosides attenuated ferroptosis agonist Erastin-induced ferroptosis in PC12 cells. Then, gypenosides ameliorated corticosterone-induced ferroptosis in PC12 cells. In terms of molecular mechanisms, gypenosides decreased the expression of Hepcidin and DMT1, and increased the expression of Ferritin and FPN1, thereby improving corticosterone-induced iron homeostasis disorders and iron accumulation. Moreover, gypenosides improved corticosterone-induced lipid peroxidation by inhibiting GLS2 expression, upregulating the expression of SLC7A11 and glutathione peroxidase 4, and reducing glutamate accumulation and GSH depletion. Gypenosides also reduced corticosterone-induced release of inflammatory cytokines, the expression of TNFR1, and the phosphorylation of NF-κB and p53 in PC12 cells. These findings indicate that gypenosides attenuate corticosterone-induced ferroptosis by inhibiting TNF-α/NF-κB signaling pathway in PC12 cells. Full article
Show Figures

Figure 1

Back to TopTop